With Josh's Grand Adventure(TM) now in the books, he and Michael return to their usual programming, examining two studies presented at the not-so-recent ASCO GU conference in San Fransisco. While the conference took place in January of this year, as the old adage goes: better late than never. In this episode, our hosts examine two studies; the CONTACT-02 study examining a combination of immunotherapy + cabozantinib in patients with metastatic castration-resistant prostate cancer, and an update from the KEYNOTE-564 that examined whether pembrolizumab had any benefit in the adjuvant treatment of renal cell cancer. Will either of these studies change practice? Fear not, for our fearless oncological explorers are on hand to guide you through the hazardous ratios and nefarious p values!

Links to studies discussed in this episode via ASCO Daily News(subscription may be required):

CONTACT-02: https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.18#:~:text=CONTACT%2D02%20is%20the%20only,Clinical%20trial%20information%3A%20NCT04446117.

KEYNOTE-564: https://dailynews.ascopubs.org/do/keynote-564-adjuvant-pembrolizumab-prolongs-survival-high-risk-clear-cell-renal-cell#:~:text=KEYNOTE%2D564%20is%20the%20first,at%20higher%20risk%20for%20recurrence.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.